Viral Hepatitis

You have full text access to this OnlineOpen article

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†

  1. Gail V. Matthews1,‡,§,*,
  2. Anchalee Avihingsanon2,‡,
  3. Sharon R. Lewin3,4,
  4. Janaki Amin1,
  5. Rungsun Rerknimitr5,
  6. Panusit Petcharapirat5,
  7. Pip Marks1,
  8. Joe Sasadeusz6,
  9. David A. Cooper1,
  10. Scott Bowden7,
  11. Stephen Locarnini7,
  12. Kiat Ruxrungtham2,8,
  13. Gregory J. Dore1

Article first published online: 11 AUG 2008

DOI: 10.1002/hep.22462

Issue

Hepatology

Hepatology

Volume 48, Issue 4, pages 1062–1069, October 2008

Additional Information

How to Cite

Matthews, G. V., Avihingsanon, A., Lewin, S. R., Amin, J., Rerknimitr, R., Petcharapirat, P., Marks, P., Sasadeusz, J., Cooper, D. A., Bowden, S., Locarnini, S., Ruxrungtham, K. and Dore, G. J. (2008), A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology, 48: 1062–1069. doi: 10.1002/hep.22462

Author Information

  1. 1

    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

  2. 2

    HIV–Netherlands Australia Thailand Red Cross AIDS Research Centre, Bangkok, Thailand

  3. 3

    Infectious Diseases Unit, The Alfred Hospital, Melbourne, Australia

  4. 4

    Department of Medicine, Monash University, Melbourne, Australia

  5. 5

    Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  6. 6

    Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia

  7. 7

    Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia

  8. 8

    Division of Allergy and Clinical Immunology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  1. ‡

    These authors contributed equally to this study.

  2. §

    fax: (61)-2-9385-0876

*Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia

  1. †

    Potential conflict of interest: Dr. Ruxrungtham advises, is on the speakers' bureau of and received grants from MSD Pharmaceuticals. He is on the speakers' bureau of and received grants from GlaxoSmithKline. He also received grants from Gilead. Dr. Dore advises, is on the speakers' bureau of, and received grants from Gilead. Dr. Locarnini is a consultant for, advises, and received grants fro, Evivar Pty Ltd and Gilead. He is a consultant for and owns stock in Pharmasset. He is also a consultant for Bristol-Myers Squibb. He holds intellectual property rights for and receipt royalties from Melbourne Health. Dr. Sasadeusz is a consultant for, is on the speakers' bureau of, and received grants from Gilead. Dr. Cooper advises, is on the speakers' bureau of, and received grants from Gilead.

Publication History

  1. Issue published online: 26 SEP 2008
  2. Article first published online: 11 AUG 2008
  3. Manuscript Accepted: 3 JUN 2008
  4. Manuscript Received: 4 MAR 2008

Funded by

  • Gilead Sciences. Grant Number: Clinical trial number NCT00192595

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (188K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Anchalee Avihingsanon, Gail V Matthews, Sharon R Lewin, Pip Marks, Jose Sasadeusz, David A Cooper, Scott Bowden, Stephen Locarnini, Greg J Dore, Kiat Ruxrungtham, Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand, AIDS Research and Therapy, 2012, 9, 1, 6

    CrossRef

  2. 2
    Wirach Maek-a-Nantawat, Anchalee Avihingsanon, Pirapon June Ohata, Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings, AIDS Research and Treatment, 2012, 2012, 1

    CrossRef

  3. 3
    Anders Boyd, Pierre-Marie Girard, Karine Lacombe, Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs, Future Virology, 2012, 7, 2, 139

    CrossRef

  4. 4
    M. Nelson, G. Amaya, N. Clumeck, C. Arns da Cunha, D. Jayaweera, P. Junod, T. Li, P. Tebas, M. Stevens, A. Buelens, S. Vanveggel, K. Boven, L. Abusamra, P. Cahn, H. E. Laplume, I. Cassetti, M. Ceriotto, M. D. Martins, A. Krolewiecki, M. Bloch, J. Gold, J. Hoy, P. Martinez, A. Rieger, N. Vetter, R. Zangerle, C. A. Da Cunha, B. Grinsztejn, J. V. Madruga, J. H. Pilotto, D. Sampaio, P. Junod, D. Kilby, A. Rachlis, S. Walmsley, J. Gerstoft, L. Mathiesen, C. Pedersen, L. Cotte, P.- M. Girard, J. M. Molina, F. Raffi, D. Vittecoq, Y. Yazdanpanah, P. Yeni, M. Fisher, M. Nelson, C. Orkin, S. Taylor, A. Lazzarin, P. Narciso, A. Orani, S. Rusconi, G. Amaya, G. Reyes-Teran, B. Rijnders, J. Santana, F. Antunes, T. Branco, R. Sarmento, E. Castro, T. Eugenio, K. Mansinho, D. Duiculescu, L. Negrutiu, L. Prisacariu, V. Kulagin, E. Voronin, A. Yakovlev, E. Baraldi, N. David, O. Ebrahim, E. Krantz, G. H. Latiff, D. Spencer, R. Wood, J. R. Arribas, J. Portilla Sogorb, E. Ribera, I. Santos Gil, K. Westling, P. Chetchotisakd, T. Sirisanthana, S. Sungkanuparph, A. Vibhagool, C.- C. Hung, H.- C. Lee, H.- H. Lin, W. W. Wong, H. Albrecht, N. Bellos, D. Berger, C. Brinson, B. Casanas, R. Elion, J. Feinberg, T. File, J. Flamm, C. Hicks, S. Hodder, C.- B. Hsiao, P. Kadlecik, H. Khanlou, C. Kinder, R. Liporace, C. Mayer, D. Mildvan, A. Mills, R. A. Myers, I. Nadeem, O. Osiyemi, M. Para, G. Pierone, B. Rashbaum, J. Rodriguez, M. Saag, J. Sampson, R. Samuel, M. Sension, P. Shalit, P. Tebas, W. Towner, A. Wilkin, J. Eron, D. Wohl, D. Baker, R. Finlayson, N. Roth, R. Colebunders, N. Clumeck, J.- C. Goffard, F. Van Wanzeele, E. Van Wijngaerden, C. R. Gonsalez, M. P. Lima, F. Rangel, A. Timerman, M. Boissonnault, J. Brunetta, J. De Wet, J. Gill, K. Kasper, J. Macleod, J. Ballesteros, R. Northland, C. Perez, L. Hongzhou, T. Li, W. Cai, H. Wu, X. Li, G. Herrera, F. Boue, C. Katlama, J. Reynes, K. Arasteh, S. Esser, G. Fatkenheuer, T. Lutz, R. Schmidt, D. Schuster, H.- J. Stellbrink, M. Johnson, E. Wilkins, I. G. Williams, A. Winston, N. Kumarasamy, P. Patil, A. Antinori, G. Carosi, F. Mazzotta, J. Andrade-Villanueva, J. G. Sierra Madero, A. Canton Martinez, A. Rodriguez-French, N. Sosa, R. Marques, C. Zorrilla, N. Dushkina, A. Pronin, O. Tsibakova, E. Vinogradova, M. Botes, F. Conradie, J. Fourie, L. Mohapi, D. Petit, D. Steyn, B. Clotet, F. Gutierrez, D. Podzamczer, V. Soriano, K. Ruxrungtham, W. Techasathit, L. Amarilis Lugo, R. Bolan, L. Bush, R. Corales, L. Crane, J. De Vente, M. Fischl, J. Gathe, R. Greenberg, K. Henry, D. Jayaweera, P. Kumar, J. Lalezari, J. Leider, R. Lubelchek, C. Martorell, K. Mounzer, C. Cohen, H. Olivet, R. Ortiz, F. Rhame, A. Roberts, P. Ruane, A. Scribner, S. Segal-Maurer, W. Short, L. Sloan, T. Wilkin, M. Wohlfeiler, B. Yangco, Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials, Journal of Antimicrobial Chemotherapy, 2012,

    CrossRef

  5. 5
    Olivier Lada, Anne Gervais, Michel Branger, Gilles Peytavin, Benedicte Roquebert, Gilles Collin, Gil Fraqueiro, Rami Moucari, Gwen Hamet, Michelle Martinot-Peignoux, Sophie Matheron, Patrick Marcellin, Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G, Liver International, 2012, 32, 1
    Direct Link:
  6. 6
    Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Zakim and Boyer's Hepatology, 2012,

    CrossRef

  7. 7
    Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans, Infection and Chemotherapy, 2011, 43, 2, 89

    CrossRef

  8. 8
    Navin Paul, Steven-Huy Han, Combination Therapy for Chronic Hepatitis B: Current Indications, Current Hepatitis Reports, 2011, 10, 2, 98

    CrossRef

  9. 9
    H. N. Kim, J. Scott, A. Cent, L. Cook, R. A. Morrow, B. Richardson, K. Tapia, K. R. Jerome, G. Lule, G. John-Stewart, M. H. Chung, HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya, Journal of Viral Hepatitis, 2011, 18, 10
    Direct Link:
  10. 10
    Gail V. Matthews, Prince Manzini, Zonghui Hu, Paul Khabo, Patrick Maja, Gugu Matchaba, Phumele Sangweni, Julie Metcalf, Nicholaas Pool, Susan Orsega, Sean Emery, Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa, AIDS, 2011, 25, 14, 1727

    CrossRef

  11. 11
    David M Iser, Anchalee Avihingsanon, Naruemon Wisedopas, Alexander J Thompson, Alison Boyd, Gail V Matthews, Stephen A Locarnini, John Slavin, Paul V Desmond, Sharon R Lewin, Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression, AIDS, 2011, 25, 2, 197

    CrossRef

  12. 12
    Helen Kovari, Rainer Weber, Influence of antiretroviral therapy on liver disease, Current Opinion in HIV and AIDS, 2011, 6, 4, 272

    CrossRef

  13. 13
    Maria Mendes-Correa, João RR Pinho, Michele S Gomes-Gouvea, Adriana C da Silva, Cristina F Guastini, Luiz G Martins, Andréa G Leite, Mariliza H Silva, Reinaldo J Gianini, David E Uip, Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil, BMC Infectious Diseases, 2011, 11, 1, 247

    CrossRef

  14. 14
    Derek Yu, Jenny Heathcote, Tenofovir in the treatment of chronic hepatitis B, Therapy, 2011, 8, 5, 527

    CrossRef

  15. 15
    J. A. Perez-Molina, M. Diaz-Menendez, M. N. Plana, J. Zamora, R. Lopez-Velez, S. Moreno, Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials, Journal of Antimicrobial Chemotherapy, 2011, 67, 2, 312

    CrossRef

  16. 16
    Christian A. Engell, Vinh Philip Pham, Robert S. Holzman, Judith A. Aberg, Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients, ISRN Gastroenterology, 2011, 2011, 1

    CrossRef

  17. 17
    G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, M Fisher, Y Gilleece, R Gilson, A Freedman, R Kulasegaram, K Agarwal, C Sabin, C Deacon-Adams, British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010, HIV Medicine, 2010, 11, 1
    Direct Link:
  18. 18
    Theodora E.M.S. de Vries–Sluijs, Jurriën G.P. Reijnders, Bettina E. Hansen, Hans L. Zaaijer, Jan M. Prins, Suzan D. Pas, Martin Schutten, Andy I.M. Hoepelman, Clemens Richter, Jan W. Mulder, Rob A. de Man, Harry L.A. Janssen, Marchina E. van der Ende, Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus, Gastroenterology, 2010, 139, 6, 1934

    CrossRef

  19. 19
    Lionel Piroth, Stanislas Pol, Karine Lacombe, Patrick Miailhes, Agathe Rami, David Rey, Veronique Loustau-Ratti, Philippe Morlat, Isabelle Goderel, Damien Sene, Eric Rosenthal, Fabrice Carrat, Patrice Cacoub, Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study, Journal of Hepatology, 2010, 53, 6, 1006

    CrossRef

  20. 20
    MARK S. SULKOWSKI, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  21. 21
    MARGARET JAMES KOZIEL, CHLOE LYNNE THIO, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  22. 22
    Norah A. Terrault, Benefits and risks of combination therapy for hepatitis B, Hepatology, 2009, 49, S5
    Direct Link:
  23. 23
    Martin Potter, Marina B Klein, Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B, HIV Therapy, 2009, 3, 2, 189

    CrossRef

  24. 24
    Gail V Matthews, Eric Seaberg, Gregory J Dore, Scott Bowden, Sharon R Lewin, Joe Sasadeusz, Pip Marks, Zachary Goodman, Frances H Philp, Yiwei Tang, Stephen Locarnini, Chloe L Thio, Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals, AIDS, 2009, 23, 13, 1707

    CrossRef

  25. 25
    David M Iser, Sharon R Lewin, Future directions in the treatment of HIV–HBV coinfection, HIV Therapy, 2009, 3, 4, 405

    CrossRef

  26. 26
    Chloe L. Thio, Hepatitis B and human immunodeficiency virus coinfection, Hepatology, 2009, 49, S5
    Direct Link:
  27. 27
    K. Lacombe, J. Bottero, M. Lemoine, A. Boyd, P. M. Girard, HIV/hepatitis B virus co-infection: current challenges and new strategies, Journal of Antimicrobial Chemotherapy, 2009, 65, 1, 10

    CrossRef

  28. 28
    Alice M. Jenh, Chloe L. Thio, Paul A. Pham, Tenofovir for the Treatment of Hepatitis B Virus, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009, 29, 10
    Direct Link:
  29. 29
    Colleen F. Kelley, Wendy S. Armstrong, Update on immune reconstitution inflammatory syndrome: Progress and unanswered questions, Current Infectious Disease Reports, 2009, 11, 6, 486

    CrossRef

  30. 30
    Sharon R. Lewin, Ruy M. Ribeiro, Anchalee Avihingsanon, Scott Bowden, Gail Matthews, Pip Marks, Stephen A. Locarnini, Kiat Ruxrungtham, Alan S. Perelson, Gregory J. Dore, Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy, Hepatology, 2009, 49, 4
    Direct Link:
  31. 31
    Vincent Soriano, Pablo Rivas, Marina Nuñez, Editorial Commentary:Risks and Benefits of Using Antiretroviral Therapy in HIV‐Infected Patients with Chronic Hepatitis B in Developing Regions, Clinical Infectious Diseases, 2008, 47, 11, 1486

    CrossRef

  32. 32
    Erik De Clercq, Discovery and Development of Tenofovir Disoproxil Fumarate,
    Direct Link:
  33. 33
    Erik Clercq, HIV Reverse Transcriptase Inhibitors, Burger's Medicinal Chemistry, Drug Discovery and Development,
    Direct Link:
View Full Article (HTML) Get PDF (188K)